Physician profile
Rudyard U Smith
NPI 1295784031
$5,043.93
in general payments reported to CMS, 2019-2025
34 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $822 · 2021: $1,164 · 2022: $758 · 2023: $591 · 2024: $661 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,091.09 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Astrazeneca Pharmaceuticals Lp | $849.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $702.43 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $355.16 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $267.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $259.91 | 2019-2024 | |
| Novo Nordisk INC | $177.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $174.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $148.69 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $92.57 | 2022-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $79.81 | 2019-2022 | |
| Preventric Diagnostics, INC. | $78.88 | 2021 | |
| Gilead Sciences, INC. | $59.75 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $48.78 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $47.28 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.08 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $37.49 | 2023 | Rexulti |
| Exact Sciences Corporation | $35.60 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $33.87 | 2019-2021 | |
| Amgen INC. | $33.14 | 2022-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.40 | 2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $28.77 | 2020 | |
| Eisai INC. | $26.61 | 2024 | |
| Sun Pharmaceutical Industries INC. | $22.27 | 2021 | |
| Nevro Corp. | $21.37 | 2022 | |
| Abbott Laboratories | $20.70 | 2023 | Freestyle Libre 3 |
| Eyevance Pharmaceuticals LLC | $19.40 | 2021 | |
| Vivus LLC | $19.02 | 2022 | |
| Edwards Lifesciences Corporation | $18.15 | 2020 | |
| Philips North America LLC | $17.93 | 2024 | (Ck7) Extended Holter |
| Medline Industries Lp | $15.86 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $15.06 | 2021 | |
| Hologic Sales and Service, LLC | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudyard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.